Introduction
- Our Generics Line
Ranbaxy Laboratories Limited (RLL) entered the U.S. generic
pharmaceutical market in 1994 with the filing of five ANDAs.
Upon approval from the U.S. FDA in 1997, RLL, through its subsidiary
Ranbaxy Pharmaceuticals Inc. (RPI), introduced its first product
- Cefaclor – in the U.S in January 1998.
Since then, RPI's generic line has experienced successful and
dramatic growth every year. Today, RPI submits an average of
20+ ANDAs every year with an average approval
cycle of 12 months.
This phenomenal growth is due, in part, to vertical integration.
Simply put, this means that RPI has total control of many of
its products, by performing every step in the process from producing
the active ingredient, and processing and manufacturing, to
delivering the finished dosage form. Vertical integration results
in a greatly streamlined and efficient process.
RPI makes popular anti-infective products, as well as quality
anti-expectorants, gastrointestinal, cardiovascular, NSAID,
analgesic, and CNS products. Generic products are manufactured
as capsules, tablets and suspensions, and are manufactured at
U.S. FDA approved plants. RPI products are sold through various
chains, wholesalers, generic distributors and hospitals.
RPI is poised for future growth and success with its extensive
generic pharmaceuticals portfolio.
|
